Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma
Year: 2019
Type: article
Abstract: = .003). On multivariate analysis stratified by transplant status, achievement of ≥VGPR after 2 cycles was not associated with improved PFS (hazard ratio [95% confidence interval]; transplant cohort, 1.1 [0.7-1.6]; nontransplant cohort, 1.2 [0.8-1.7]) or OS (transplant cohort, 1.6 [0.9-2.9]; nontransplant cohort, 1.5 [1.0-2.4]). Covariates in the model included high-risk cytogenetics, ISS stage III, triplet therapy, creatinine ≥2 mg/dL, light chain disease, and age. Although patients with high-risk disease are more likely to achieve early response, a rapid achievement of a deep response by itself does not affect long-term outcomes.
Source: Blood Advances
Authors: Nidhi Tandon, Surbhi Sidana, S. Vincent Rajkumar, Morie A. Gertz, Francis K. Buadi, Martha Q. Lacy, Prashant Kapoor, Wilson I. Gonsalves, Angela Dispenzieri, Taxiarchis V. Kourelis, Rahma Warsame, David Dingli, Amie L. Fonder, Suzanne R. Hayman, Miriam A. Hobbs, Yi Lisa Hwa, Robert A. Kyle, Nelson Leung, Ronald S. Go, John A. Lust, Stephen J. Russell, Shaji K. Kumar
Institution: Mayo Clinic
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,800
Funder: National Cancer Institute
Award: G1016754749
OpenAlex ID: W2920120295